Four more COVID-19 vaccines on cards in India, check prices here
Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia s Sputnik-V vaccine
BusinessToday.In | January 12, 2021 | Updated 18:36 IST
(Picture Courtesy: Youtube @PIB India)
Indian health regulators are looking at four more COVID-19 vaccines, said Health Secretary Rajesh Bhushan on Tuesday.
Among these vaccines are those developed by Zydus Cadila, Biological E and Gennova, along with Russia s Sputnik-V vaccine.Zydus Cadila finished Phase 2 clinical trials in December last year and has been granted approval for Phase 3 trials in India.
Similarly, the Phase 2 clinical trials of Russia s Sputnik-V COVID-19 vaccine have also concluded and Phase 3 trials are being carried out by its Indian partner Dr Reddy s Laboratories.
Karnataka received 6.5-lakh doses of Covishield vaccine from Serum Institute of India (SII) at Pune for administering it to 16-lakh frontline warriors across the state, said state Health Minister K. Sudhakar on Tuesday."We have received .
Bharat Biotech inks pact with Precisa Med to supply Covaxin to Brazil
Premium
The supplies of Covaxin will be prioritized for public market, through direct procurement by Brazil government
The supplies of Covaxin to private market would be based upon receipt of market authorization from Brazilian regulatory authority ANVISA
Share Via
Read Full Story
Bharat Biotech on Tuesday announced that it has signed an agreement with Precisa Medicamentos for the supply of its indigenously manufactured Covid-19 vaccine Covaxin to Brazil.
The supplies of Covaxin will be prioritized for public market, through direct procurement by Brazil government, the company said in a statement.